From 2010-2014 NobleGen Biosciences commercialized next generation DNA sequencing technology, licensed from Harvard and Boston Universities, based on multicolor optical read-out of single molecules fed through solid state nanopore arrays. The unique advantage of the Optipore approach is very high degree of parallelization and accuracy in the read-out of converted biomolecules.
View Top Employees from NobleGen Biosciences, Inc.| Website | https://www.noblegenbio.com |
| Revenue | $1 million |
| Employees | 1 (0 on RocketReach) |
| Founded | 2010 |
| Address | 58 Elsinore St, Concord, Massachusetts 01742, US |
| Phone | (978) 405-2533 |
| Technologies |
JavaScript,
HTML,
Nginx
+2 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541711 Companies |
Looking for a particular NobleGen Biosciences, Inc. employee's phone or email?
NobleGen Biosciences, Inc. Questions
The NobleGen Biosciences, Inc. annual revenue was $1 million in 2024.
NobleGen Biosciences, Inc. is based in Concord, Massachusetts.
The NAICS codes for NobleGen Biosciences, Inc. are [54171, 5417, 54, 541, 541711].
The SIC codes for NobleGen Biosciences, Inc. are [80, 283, 28].
Related Companies
